For Immediate Release
Chicago, IL – February 27, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Celgene Corp. , Charles River Laboratories International, Inc. (CRL - Free Report) , Catalent, Inc. (CTLT - Free Report) and Aeterna Zentaris Inc. .
Here are highlights from Tuesday’s Analyst Blog:
4 Drug Stocks to Buy Despite Price Hearing Challenges
The much-anticipated Congressional hearing over unfair drug pricing is slated to take place on Feb 26. The hearing will establish ground rules for fair drug pricing in America and make way for more government involvement. Such events are widely expected to mar healthcare sector performance this year.
However, the reference pricing model, due to be established in 2020, will propel gains for the sector. Moreover, healthcare IPOs and venture funding will take centerstage this year. Therefore, the hearing isn’t expected to do much damage this year. Under such circumstances, investing in drug stocks seems like a wise choice.
One of the top priorities of President Trump’s administration has been drug pricing. As a matter of fact, both Congress and Trump have come together to deal with this. Expected to disrupt the pharma sector, a congressional hearing is set to take place today.
The hearing, called "Drug Pricing in America: A Prescription for Change, Part II," seeks to lower the unnecessarily high healthcare costs in America. Currently, an American citizen spends about $11,212 on average per year on healthcare. Further, drugmakers might face legislative actions over steep drug pricing practices over the past few years.
The House Oversight and Senate Finance committees will be led by senators Chuck Grassley and Ron Wyden. Both the leaders opined that prescription drug costs are excruciatingly high and the current trend increase in drug prices is "unsustainable."
Reference Pricing Model to Benefit Both Parties
Per the terms of the latest proposal by the Centre for Medicare and Medicaid Services (CMS), a new drug pricing model is to be established. To be in use from 2020 through 2025, this model will be a reference pricing model.
The model will use the International Pricing Index (IPI) to reach a consensus by referring to international prices for selected Part B drugs. Further, new drugs will be assessed by a joint committee of providers, insurers and hospital organizations. Further, patient groups will have a non-voting position in the committee.
In case a new drug does not have any available alternatives, the committee will discard any patient cost-sharing on the drug. This will significantly reduce the out-of-pocket (OOP) costs for the patient.
However, if an alternative to the new drug is available and the joint committee believes that it does not offer more benefits than the available options, the drug will be allotted to a specific therapeutic class on which the reference pricing will then apply. Thus, a healthcare purchaser will have the freedom to establish the minimum price he/she is willing to pay out-of-pocket for the drug.
However, the customers will have to take into account the minimum as well as the median price of that drug in any therapeutic class. Such an arrangement distributes costs evenly between the manufacturer and the patient and establishes a fair pricing system which is beneficial to both parties.
4 Best Choices
A steady influx of foreign as well as domestic investments in U.S. healthcare has gone a long way in boosting gains for the space. Further, a burgeoning economy has necessitated diversification by the top players in the industry. Given such positives, any decision to lower drug prices will not hamper the space.
In this context, we have selected four drug stocks that are expected to gain from these factors. These stocks carry a Zacks Rank #1 (Strong Buy) or 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Celgene Corp. is engaged in the discovery and development of therapies for treatment of cancer and inflammatory diseases.
The company is based out of Summit, NJ and sports a Zacks Rank #1. The expected earnings growth rate for the current year is 20.51%. The Zacks Consensus Estimate for the same has improved 5.3% over the past 60 days.
Charles River Laboratories International, Inc. is a provider of drug discovery, non-clinical development and safety testing services.
The company is based out of Wilmington, MA and has a Zacks Rank #2. The expected earnings growth rate for the current year is 7.43%. The Zacks Consensus Estimate for the same has climbed 1.6% over the past 60 days.
Catalent, Inc. is engaged in the development of solutions for drugs, biologics and other health products.
The company is based out of Somerset, NJ and carries a Zacks Rank #2. The expected earnings growth rate for the current year is 5.37%. The Zacks Consensus Estimate for the same has risen 1.7% over the past 60 days.
Aeterna Zentaris Inc. is engaged in the development of pharmaceutical therapies used in oncology and endocrinology.
The company is based out of Somerset, NJ and carries a Zacks Rank #2. The expected earnings growth rate for the current year is more than 100%. The Zacks Consensus Estimate for the same has moved 15.8% up over the past 60 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.